The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Elrexfio elranatamab PRIMEConditionalAdditional monitoring | Pfizer Europe MA EEIG | Multiple Myeloma | 🇪🇺 EU 2023-12-07 | Order → |
| Elucirem gadopiclenol Additional monitoring | Guerbet | Magnetic Resonance Imaging | 🇪🇺 EU 2023-12-07 | Order → |
| Veoza fezolinetant Additional monitoring | Astellas Pharma Europe B.V. | Menopause; Hot Flashes | 🇪🇺 EU 2023-12-07 | Order → |
| Vueway gadopiclenol Additional monitoring | Bracco Imaging S.p.A. | Magnetic Resonance Imaging | 🇪🇺 EU 2023-12-07 | Order → |
| Zilbrysq zilucoplan Additional monitoring | UCB Pharma S.A. | Myasthenia Gravis | 🇪🇺 EU 2023-12-01 | Order → |
| Pylclari piflufolastat (18F) Additional monitoring | Curium Pet France | Prostatic Neoplasms | 🇪🇺 EU 2023-11-27 | Order → |
| Yorvipath palopegteriparatide OrphanAdditional monitoring | Ascendis Pharma Bone Diseases A/S | Hypoparathyroidism | 🇪🇺 EU 2023-11-17 | Order → |
| Ebglyss lebrikizumab Additional monitoring | Almirall, S.A. | Dermatitis, Atopic | 🇪🇺 EU 2023-11-16 | Order → |
| Aqumeldi enalapril maleate | Proveca Pharma Limited | Heart Failure | 🇪🇺 EU 2023-11-15 | Order → |
| Catiolanze latanoprost | Santen Oy | Glaucoma, Open-Angle | 🇪🇺 EU 2023-11-15 | Order → |
| Finlee dabrafenib Orphan | Novartis Europharm Limited | Glioma | 🇪🇺 EU 2023-11-15 | Order → |
| Herwenda trastuzumab BiosimilarAdditional monitoring | Sandoz GmbH | Breast Neoplasms; Stomach Neoplasms | 🇪🇺 EU 2023-11-15 | Order → |
| Vanflyta quizartinib Additional monitoring | Daiichi Sankyo Europe GmbH | Leukemia, Myeloid | 🇪🇺 EU 2023-11-06 | Order → |
| Jaypirca pirtobrutinib ConditionalAdditional monitoring | Eli Lilly Nederland B.V. | Lymphoma, Mantle-Cell | 🇪🇺 EU 2023-10-30 | Order → |
| Zoonotic Influenza Vaccine Seqirus zoonotic influenza vaccine (H5N8) (surface antigen, inactivated, adjuvanted) | Seqirus S.r.l. | Influenza A Virus, H5N8 Subtype | 🇪🇺 EU 2023-10-09 | Order → |
| Degarelix Accord degarelix Generic | Accord Healthcare S.L.U. | Prostatic Neoplasms | 🇪🇺 EU 2023-09-29 | Order → |
| Tepkinly epcoritamab ConditionalAdditional monitoring | AbbVie Deutschland GmbH & Co. KG | Lymphoma, Large B-Cell, Diffuse | 🇪🇺 EU 2023-09-22 | Order → |
| Tyruko natalizumab BiosimilarAdditional monitoring | Sandoz GmbH | Multiple Sclerosis, Relapsing-Remitting; Multiple Sclerosis | 🇪🇺 EU 2023-09-22 | Order → |
| Apretude cabotegravir | ViiV Healthcare B.V. | HIV Infections | 🇪🇺 EU 2023-09-15 | Order → |
| Enrylaze crisantaspase Additional monitoring | Jazz Pharmaceuticals Ireland Limited | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 🇪🇺 EU 2023-09-15 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.